The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Open accessAbstract
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The average historical PFS6 based on the above studies is 15.3 ± 3.8%”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [25]
In the citing paper
“and the average historical TTP is 9.5 ± 1.6 weeks.”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [25]
In the citing paper
“OS averaged 29.3 ± 6 weeks (see SI Table 2).”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [25]
In the citing paper
“Efficacy analysis was performed for 10 recurrent GBM patients by comparing TTP, PFS6, and OS in recurrent GBM patients treated with the NovoTTF-100A device with the TTP, PFS6, and OS of recurrent GBM patients in a literature based historical control group (10, 25–28).”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005 · cited 1×
“The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 [+3]) (Aaronson et al, 1993; Osoba et al, 1997) and the Brain Cancer Module 20 (BCM20) (Osoba et al, 1996) questionnaires were used to measure HRQL. Questionnaires were administered on day 1…”
MethodSelf-citationJaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982 · cited 1×
“A 10-unit change on a 0–100 scale was deemed significant if it lasted for at least 8 weeks (Jaeschke et al, 1989; Juniper et al, 1994; King, 1996; Ware et al, 1998).”
Background(1994) · Medical Entomology and Zoology · Cited by 4,156
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016 · cited 1×
“Meaning of changes in HRQL scores was addressed by the method of Osoba et al (1998).”
MethodSelf-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824 · cited 1×
“A 10-unit change on a 0–100 scale was deemed significant if it lasted for at least 8 weeks (Jaeschke et al, 1989; Juniper et al, 1994; King, 1996; Ware et al, 1998).”
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30
King, M. T. (1996) · Quality of Life Research · doi:10.1007/bf00439229 · Cited by 666
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E. S., Blackledge, G. R. P., Slack, J., Rustin, G. J. S., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M. F. G., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488 · cited 3×
“TMZ has notable antitumour activity against recurrent GBM, recurrent anaplastic astrocytoma, and advanced malignant melanoma, and other refractory cancers (Newlands et al, 1992, 1996; O’Reilly et al, 1993; Bleehen et al, 1995; Bower et al, 1997).”
BackgroundResultMayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K., & Ludwig, H. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8 · Cited by 407
Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L. M., Stone, R., BAIG, G. U., Goddard, C. P., Gibson, N. W., & Slack, J. A. (1987) · PubMed · Cited by 387
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 928
Locoregional Treatment of Brain Tumors
Kunikowska, J., Morgenstern, A., Bruchertseifer, F., & Królicki, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-63067-0_35 · Cited by 1
Management of Recurrent Gliomas
Harsh, G. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6839-6.10010-3 · Cited by 1
An Overview of High-grade Glioma: Current and Emerging Treatment Approaches
Kavya, S., & Reghu, R. (2020) · Current Cancer Therapy Reviews · doi:10.2174/1573394716666200721155514 · Cited by 1
The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck
Wilson, M. A., & Fecher, L. A. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2020.11.006 · Cited by 1
Glioma of the Central Nervous System Surveillance Counterpoint: Australia
Lehman, M., & Barton, M. B. (2012) · Humana Press eBooks · doi:10.1007/978-1-60327-969-7_105 · Cited by 1
Supratentorial High-Grade Gliomas
Sanchez-Mejia, R. O., Banerjee, A., & Gupta, N. M. (2006) · Springer eBooks · doi:10.1007/3-540-31260-9_25 · Cited by 1
Overview of Pathology and Treatment of Primary Brain Tumors
Newton, H. B., Ray‐Chaudhury, A., & Malkin, M. G. (2008) · Elsevier eBooks · doi:10.1016/b978-012370863-2.50004-x · Cited by 1
Central Neurotoxicity of Chemotherapy
López‐Gómez, L., Abalo, R., & Vera, G. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_345-1 · Cited by 1
Ramanan, V. A., Jeeva, S., & Sowmiya, K. R. (2023) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2023.1.9 · Cited by 1
Central Neurotoxicity of Chemotherapy
López‐Gómez, L., Abalo, R., & Vera, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_345-2 · Cited by 1
TEMOZOLOMIDE IN MALIGNANT ASTROCYTIC GLIOMAS
Borisov, K. E., & Sakayeva, D. D. (2012) · Russian Journal of Oncology · doi:10.17816/onco39963 · Cited by 1
Malignant Glioma: Viewpoint—Chemotherapy
Stupp, R., Homicskó, K., & Cairncross, J. G. (2015) · Springer eBooks · doi:10.1007/978-1-4614-8363-2_19 · Cited by 1
Radiosensitizers in Brain Cancer
Milker-Zabel, S. (2006) · American Journal of Cancer · doi:10.2165/00024669-200605060-00003 · Cited by 1
Immunotherapy with Dendritic Cells and Newcastle Disease Virus in Glioblastoma Multiforme
Neelhut, T., Marx, D., Neelhut, J., & Fändrich, F. (2011) · InTech eBooks · doi:10.5772/22074 · Cited by 1
“In this context, an oral alkylating agent, temozolomide, has demonstrated antitumor activity as a single agent in the treatment of glioblastoma patients (Newlands et al., 1997; Stupp et al., 2001, 2005; Yung et al., 2000).”
BackgroundCentral Nervous System Complications in Patients Undergoing Chemotherapy
Psimaras, D., Leclercq, D., Ricard, D., & Delattre, J. (2014) · Medical radiology · doi:10.1007/174_2014_1050 · Cited by 1
Antiangiogenic Therapy for Glioblastoma
Jahangiri, A., Flanigan, P. M., & Aghi, M. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47660-7.00010-0 · Cited by 1
Ahluwalia, M. S., & Peereboom, D. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-185-7_16 · Cited by 1
Targeted Radiotherapy of Central Nervous System Malignancies
Zalutsky, M. R., Reardon, D. A., & Bigner, D. D. (2010) · doi:10.1002/9780470613214.ch5 · Cited by 1
Primäre Hirntumoren bei Erwachsenen
Weller, M., Krauseneck, P., Kath, R., Kortmann, R., & Schmoll, H. (2006) · Springer eBooks · doi:10.1007/3-540-31303-6_297 · Cited by 1
The Prevalence and Impact of Neurologic Disease in Cancer
Kaal, E. C. A., & Vecht, C. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-412-4_1 · Cited by 1
10 Questions About the Use of Bevacizumab in the Management of Recurrent Malignant Gliomas
Chamberlain, M. C. (2010) · The Neurologist · doi:10.1097/nrl.0b013e3181c78aa2 · Cited by 1
“Patients with recurrent anaplastic gliomas have shown better outcomes in historical trials, with response rates of approximately 35% and PFS-6 rates of between 17% and 47%.(12,14,15) In the largest clinical trial(9) to evaluate bevacizumab in patients with recurrent glioblastomas to date, 38% (31 of 82) of patients tr…”
BackgroundState-of-the-art Therapy for Glioblastoma Multiforme
Friedman, H. S. (2007) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2007.00.2.103 · Cited by 1
Self-citationCentral Nervous System and Peripheral Nerves
Ormond, D. R., Bouras, A., Moore, M., Gary, M. F., Warren, P. P., Prabhu, R. S., Egan, K. M., Rangaraju, S., Appin, C., Hadjipanayis, C. G., et al. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch40 · Cited by 1
Self-citationPrimäre Hirntumoren bei Erwachsenen
Weller, M., Krauseneck, P., Kath, R., Kortmann, R., & Schmoll, H. (2006) · Springer eBooks · doi:10.1007/3-540-31303-6_193 · Cited by 1
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad085 · Cited by 1
Development of Liposome Drug Delivery Systems for Anti-Glioma Therapy
Jain, M. (2012) · CLOK (University of Central Lancashire) · Cited by 1
[New therapeutic approaches in glioblastomas].
Carpentier, A. F. (2005) · PubMed · doi:10.1016/s0035-3787(05)85032-5
Quality of life in oncology with emphasis upon neuro-oncology
Ali, K. C. (2006) · Frontiers in bioscience · doi:10.2741/2071
Studies on viral gene transfer and angiogenesis inhibition in experimental glioma models
Huszthy, P. C. (2006) · NORA - Norwegian Open Research Archives
FUNCTION AND REGULATION OF MATRIX METALLOPROTEINASE-1 IN GLIOBLASTOMA MULTIFORME
Anand, M. (2010) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/my57-kx07
“Clinical trials using TMZ have shown that it can be regarded as an oral single-agent drug superior to other drugs for recurrent GBM patients (Yung et al., 2000).”
BackgroundGlioma and Other Neuroepithelial Neoplasms
Palka, K. T., Mobley, B. C., Perkins, S. M., Cooper, M. K., Sills, A. K., & Moots, P. L. (2012) · doi:10.1002/9781118464557.ch58
Malignome des zentralen Nervensystems (ZNS)
Schalhorn, A., & Pecher, G. (2012) · Elsevier eBooks · doi:10.1016/b978-3-437-21212-3.10024-4
Recurrent Malignant Primary Brain Tumor: the Pathophysiology and Management
Tse, V., & Babu, H. (2011) · InTech eBooks · doi:10.5772/22080
“another chemo-agent PCB which produced an 8% PFS-6 (Yung et al., 2000).”
InfluentialNuevos quimioterápicos en Neurooncología
Balañá, C., Rosell, R., Alabau, R. B., Arellano, A., Cirauqui, B., & Morán, T. (2003) · Revista de Oncología · doi:10.1007/bf02712835
Immunotherapy for malignant gliomas: current status and perspective
Borisov, K. E., & Sakaeva, D. (2015) · Malignant tumours · doi:10.18027/2224-5057-2015-2-22-39
“Тем не менее даже без учета этого исследования показатели ОВ при вакцинотерапии рецидивных МГБ существенно превосходили данные исторического контроля [28].”
Malignome des zentralen Nervensystems (ZNS)
Pecher, G. (2007) · Elsevier eBooks · doi:10.1016/b978-343723770-6.50027-2
Beresford, M. J., Power, D., Alexander, E. J., Brock, C. S., Thompson, J., Roncaroli, F., Waldman, A. D., van Dellen, J., & Glaser, M. G. (2006) · American Journal of Cancer · doi:10.2165/00024669-200605060-00008
Combined chemotherapy and immunotherapy against experimental malignant brain tumors
Fritzell, S. (2013) · Lund University Publications (Lund University)
Plasma cell neoplasm in conjunction with glioblastoma of the conus medullaris.
Williams, S. R., Parker, J. R., Martin, A. W., Vitaz, T. W., & Parker, J. C. (2011) · PubMed
de Oliveira, M. S. (2008) · Americanae (AECID Library)
Temozolomide does not increase overall survival in recurrent malignant glioma
Stupp, R. (2002) · Evidence-based Oncology · doi:10.1054/ebon.2002.0030
Image guidance in malignant gliomas: a focused strategy
Katsoulakis, E., Beal, K. P., & Yamada, Y. J. (2012) · CNS Oncology · doi:10.2217/cns.12.21
Temozolomide – what regimen in what situation?
Hau, P. (2009) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-009-0127-5
“In relapse, the same adjuvant regimen is approved [ 13 ].”
BackgroundLos «tiempos» —timing— en Neurooncología
Parera, I. C., Báez, A., Roffo, A. G., Kuchkaryan, V., Barros, J. M., Halfón, M. J., Tamborini, N. M., Larrarte, G. A., Blumenkrantz, Y., de Robles, P. A., et al. (2014) · Neurología Argentina · doi:10.1016/j.neuarg.2014.05.005
Analiza składników DNA guzów nowotworowych mózgu u człowieka
Barciszewska, A. (2010)
Phase II Trial of Lower Dose Bevacizumab and Irinotecan in Relapsed High Grade Gliomas
Kairouz, V., Kamar, F. G., Dimassi, H. I., & Comair, Y. G. (2015) · Journal of Cancer Science and Clinical Oncology · doi:10.15744/2394-6520.1.201
Nouvelles thérapeutiques ciblées dans les glioblastomes
Marantidou, A., & Carpentier, A. (2009) · ONCOLOGIE · doi:10.1007/s10269-008-1035-8
Walsh, N., & Fleet, A. (2007) · Journal of Radiotherapy in Practice · doi:10.1017/s1460396907005110
“Yung et al.(15) designed a larger Phase II study that implemented a TMZ schedule for GBM patients at first relapse of 150 200 mg/m(2)/day over 5 days, repeated over a 28-day cycle.”
BackgroundRecent advances in the medical therapy of high-grade gliomas
Mason, W. P., & Stupp, R. (2006) · Future Neurology · doi:10.2217/14796708.1.6.831
Tumorprogress versus therapieinduzierte Veränderungen (Pseudoprogression) bei malignen Astrozytomen
Platten, M. (2009) · Onkopipeline · doi:10.1007/s15035-009-0139-y
Temozolomide in the treatment of malignant brain tumors in children
Korab-Chrzanowska, E., & Kwiatkowski, S. (2003) · Jagiellonian University Repository (Jagiellonian University)
Enhancing Dendritic Cell Migration to Drive Antitumor Responses
Batich, K. A. (2017)
Les tumeurs gliales malignes de l’adulte
Guillamo, J., Geffrelot, J., & Carpentier, A. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0021-9_35
Sathornsumetee, S., & Reardon, D. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-166-0_9
Opciones terapéuticas del astrocitoma de bajo grado supratentorial en el adulto
Prat-Acín, R., & Senabre, I. G. (2008) · Archivos de Neurociencias
TEMOZOLOMIDE AND BEVACIZUMAB THERAPY IN ADVANCED HEMANGIOPERICYTOMA/ SOLITARY FIBROUS TUMOR
Park, M. S. (2010) · Digital Commons-TMC (Texas Medical Center)
Role of Pharmacists in Innovative Chemotherapy :
Ishikawa, K., Maeda, M., Goto, Y., Gajjar, A. J., & Nabeshima, T. (2007) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.33.987
Manejo de los tumores hipofisarios agresivos
Aller, J., Michelena, M. C., García, N. P., & García, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-538-7.00011-3
Lassman, A. B., Schifter, D., & Corn, B. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00025-0
Chemoradiotherapy: Radiation Total Dose and Fractionation
Chiesa, S., Balducci, M., Ferro, M., Alitto, A. R., & Valentini, V. (2016) · Current clinical pathology · doi:10.1007/978-3-319-28305-0_4
Bodell, W. J., Gaikwad, N. W., Miller, D. L., & Berger, M. S. (2003) · Cancer Epidemiology and Prevention Biomarkers
Glioblastoma Tumours: Complex Challenges and Deadly Outcomes
Kilian, A. (2016) · The Meducator · doi:10.15173/m.v1i27.1164
Izquierdo, C., & Ducray, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-40232-1_8
Chemotherapy for Malignant Gliomas
Kochi, M., & Ushio, Y. (2002) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.11.347
Novel Therapeutic Approaches to Induce Autophagy in Brain Cancer
Conway, G. E. (2016) · Arrow - TU Dublin (Technological University Dublin) · doi:10.21427/d7632v
“A phase II study carried out by (Yung et al, 2000) which compared TMZ with single agent pro-carbazine in 225 GBM patients with first relapse.”
BackgroundA Case Report of Recurrent Glioblastoma treated with Bevacizumab and Irinotecan
Maekawa, H., Toda, H., Aoki, T., & Ishikawa, M. (2009) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.18.145
Burnet, N. G., Jena, R., Jefferies, S., Kirkby, N. F., & Treasure, F. (2008) · British Journal of Neurosurgery · doi:10.1080/02688690802150634
El-Ghoneimy, E., Abdullah, M., Mostafa, E., Elsayed, Z. M. A.-H., Al‐Booz, H., & Nazmy, N. (2006) · Research in Oncology · doi:10.21608/resoncol.2006.356
Other Secondary Headaches in the Emergency Department
Marmura, M. J., & Friedman, B. W. (2017) · Cambridge University Press eBooks · doi:10.1017/9781316819388.007
Hofer, S., & Merlo, A. B. B. (2002) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2002.04606
Chemotherapy of Pediatric High-Grade Gliomas
Upadhyaya, S. A., & Broniscer, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00044-9
Disseminated strongyloidiasis in immunosuppressed patient
Silva, M. K. P. (2018) · MOJ Clinical & Medical Case Reports · doi:10.15406/mojcr.2018.08.00273
Chemotherapeutics and Their Efficacy
Phillips, H. W., & Chi, A. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47660-7.00009-4
da Fonseca, C. O., da Fonseca, C. O., Gattass, C. R., Linden, R., Carvalho, M. D. G., Futuro, D. O., & Quírico‐Santos, T. (2018) · JBNC - JORNAL BRASILEIRO DE NEUROCIRURGIA · doi:10.22290/jbnc.v18i3.629
Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma
Agarwala, S. S., Middleton, M. R., & Atkins, M. B. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_54
Abdullah, K. G., Miller, J. A., Adamson, C., & Brem, S. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47660-7.00011-2
Comparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma
Li, R., Li, C., Cai, Z., Li, L., Wei, L., Qian, Z., & Zhou, D. (2020) · Medicine · doi:10.1097/md.0000000000020011
Areeb, Z. (2020) · Minerva Access (University of Melbourne)
Rasheed, M. O., Bhuiyan, M. Z. R., Mollah, N. U., Islam, M. R., Hasan, T., & Rahman, M. M. (2020) · Scholars Journal of Applied Medical Sciences · doi:10.36347/sjams.2020.v08i06.006
“Third HGG is resistant to most cytotoxic agents, the expression of MGMT promoter methylation is thought to be the major mechanism of the resistance [10].”
BackgroundEvidence-based approaches to chemotherapy for gliomas
Pellerino, A., Franchino, F., Rudà, R., & Soffietti, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-69494-0.00004-x
Weller, M., Müller, B., & Kortmann, R. (2007) · Springer eBooks · doi:10.1007/978-3-540-28978-4_24
TAPHOORN, M. J. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3072
Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy
Batich, K. A., Sampson, J. H., Khasraw, M., Friedman, H. S., & Ashley, D. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00018-x
Self-citationXie, X. (2019) · Global Journal of Reproductive Medicine · doi:10.19080/gjorm.2019.06.555694
“The 6-month PFS (PFS6) for recurrent GBM ranges from 9 to 21% [8,9,16], while PFS6 for anaplastic gliomas have ranged from 37 to 48% [17,18].”
BackgroundTop 100 Most Cited Articles on Brain Tumors
Thomas, G., Chatim, A., Chalif, E. J., Koenig, S., Almeida, N. D., & Ghosh, P. (2021) · International Journal of Neurosurgery · doi:10.11648/j.ijn.20210502.15
High-grade gliomas: a literature review. Part 2. Radiosurgical treatment
Грецких, К. В., & Токарев, А. С. (2022) · Russian journal of neurosurgery · doi:10.17650/1683-3295-2021-23-4-87-98
“Учитывая сложные изменения, возникающие в результате антиангиогенной терапии, для оценки опухолевого ответа и рецидива / прогрессирования у пациентов, получающих антиангиогенную терапию при рецидивирующей ГВСЗ, целесообразно не ограничиваться контрастным усилением на МРТ-изображениях, а максимально использовать T2 / F…”
Zentrales Nervensystem und Sinnesorgane
Engenhart‐Cabillic, R., Groß, M. W., Henzel, M., Bois, A. Z.-D., Milker-Zabel, S., & Rades, D. (2007) · Strahlentherapie · doi:10.1007/978-3-540-68520-3_16
Lieberman, F. S. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726771952.793537829
Batchelor, T. T., & van den Bent, M. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.2878
“and an intensive imaging program was part of the phase II trial demonstrating a clear biologic effect.(3) The primary end point of the phase III was PFS, and although a trend is clearly visible, it is”
BackgroundEvolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma
Agarwala, S. S., Middleton, M. R., & Atkins, M. B. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_54-1
The Prevalence and Impact of Neurologic Disease in Cancer
Vecht, C. J. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-317-0_1
Reardon, D. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6143
STAYNER, C. J., LOPEZ, R. M., & TUZZOLINO, K. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-07586-2.00034-0
Metadata
- Authors
- Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R. G., Vick, N. A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., & Levin, V. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- University of Mississippi Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of California, San Francisco (US)
- Royal Marsden NHS Foundation Trust (GB)
- University of Washington (US)
- University of Iowa Hospitals and Clinics (US)
- Barrow Neurological Institute (US)
- Memorial Hospital of Rhode Island (US)
- University of Michigan (US)
- Western Pennsylvania Hospital (US)
- Evanston Hospital (US)
- Beatson West of Scotland Cancer Centre (GB)
- Duke University (US)
- BC Cancer Agency (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- British Journal of Cancer
- Published
- 2000-09
- Volume
- 83
- Issue
- 5
- Pages
- 588-593
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2363506
- OpenAlex
- W1977392502
- Cited by
- 929
- References
- 27
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 8 · 2023: 23 · 2022: 19 · 2021: 21 · 2020: 21 · 2019: 20 · 2018: 27 · 2017: 23 · 2016: 31 · 2015: 32 · 2014: 33 · 2013: 38 · 2012: 50
- FWCI
- 21.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- temozolomide, procarbazine, glioblastoma, first relapse, progression-free survival, overall survival, health-related quality of life, alkylating agents, oral chemotherapy, treatment safety
- MeSH terms
- Temozolomide, Adult, Aged, Antineoplastic Agents, Brain Neoplasms, Dacarbazine, Female, Glioblastoma, Humans, Male, Middle Aged, Procarbazine, Prognosis, Quality of Life, Recurrence, Time Factors, Gliosarcoma, Disease-Free Survival, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
